Edition:
India

Sucampo Pharmaceuticals Inc (SCMP.OQ)

SCMP.OQ on NASDAQ Stock Exchange Global Market

16.30USD
12 Dec 2017
Change (% chg)

$0.05 (+0.31%)
Prev Close
$16.25
Open
$16.25
Day's High
$16.55
Day's Low
$15.80
Volume
761,287
Avg. Vol
168,751
52-wk High
$17.70
52-wk Low
$9.30

Summary

Name Age Since Current Position

Peter Greenleaf

47 2016 Chairman of the Board, Chief Executive Officer

Peter Pfreundschuh

48 2017 Chief Financial Officer

Max Donley

48 2014 Executive Vice President of Global Human Resources, Information Technology and Strategy

Matthias Alder

52 2017 Executive Vice President

Peter Kiener

64 2014 Chief Scientific Officer

Alex Driggs

41 2017 General Counsel, Corporate Secretary

Peter Lichtlen

47 2014 Chief Medical Officer

John Johnson

59 2016 Lead Independent Director

Paul Edick

62 2016 Director

Daniel Getman

59 2016 Director

Karen Smith

49 2017 Director

Timothy Walbert

50 2015 Director

Barbara Munder

69 2013 Independent Director

Maureen O'Connell

55 2013 Independent Director

Robert Spiegel

68 2015 Independent Director

Silvia Taylor

2014 Senior Vice President - Investor Relations and Corporate Communications

Biographies

Name Description

Peter Greenleaf

Mr. Peter Greenleaf has been appointed as the Chairman of the Board, Chief Executive Officer of the Company. He was Director of the Sucampo Pharmaceuticals Inc. Prior to his leadership of Sucampo, Mr. Greenleaf was CEO and Board member of Histogenics Corporation, a regenerative medicine company, from June 2013 through February 2014. From 2008 to June 2013, Mr. Greenleaf was employed by MedImmune LLC, the global biologics arm of AstraZeneca, where he most recently served as President. While at MedImmune, Mr. Greenleaf was instrumental in driving the expansion of MedImmune’s pipeline into over 120 clinical and pre-clinical programs and the commercialization of its marketed products. Mr. Greenleaf has also held senior commercial roles at Centocor Biotech, Inc. (now Jansen Biotechnology, Johnson & Johnson) from 1998 to 2006 and prior to that Boehringer Mannheim G.m.b.H. (now Roche Holdings) from 1996 to 1998. Mr. Greenleaf currently chairs the Maryland Venture Fund Authority, whose vision is to oversee implementation of InvestMaryland, a public-private partnership to spur venture capital investment in the state. Mr. Greenleaf is also a member of the board of directors of the Biotechnology Industry Organization (BIO), where he also serves on the Governing Board of the Emerging Companies Section. He received a Master of Business Administration degree from St. Joseph’s University and a Bachelor of Science degree from Western Connecticut State University. Our board of directors believes the characteristics that qualify Mr. Greenleaf for service on our board of directors include his leadership experience and extensive commercialization, strategic planning, and drug development experience in the biopharmaceutical industry.

Peter Pfreundschuh

Mr. Peter Pfreundschuh, CPA is appointed as the Chief Financial Officer of the Company effective March 20, 2017. Mr. Pfreundschuh served as Vice President, Finance and Chief Financial Officer of Immunomedics Inc., a biopharmaceutical company, from September 2013 to June 2016 and as a consultant to that company from June 2016 to August 2016. From November 2008 until June 2013, Mr. Pfreundschuh was the Chief Financial Officer of CircuLite Inc., a commercial medical device company. Prior to that, Mr. Pfreundschuh was the Executive Director of Business Development and Licensing for AstraZeneca Pharmaceuticals L.P. Before AstraZeneca, he served at Johnson and Johnson in a variety of capacities, including Controller of the R&D division and Controller/Director of Marketing and Global Business Analytics, as well as Chief Financial Officer/Treasurer for 3 Dimensional Pharmaceuticals, which was acquired by Johnson and Johnson. Mr. Pfreundschuh has also held management positions at Alimenterics, Inc., and American Standard Companies, Inc., and was a Senior Auditor at Ernst & Young, LLP. Mr. Pfreundschuh received an M.B.A. with a concentration in finance from Rider University, a B.S. in accounting from Rutgers University School of Business, and continued his education through the Executive Strategic Marketing Program in Healthcare at the Kellogg School of Management at Northwestern University. He is a licensed Certified Public Accountant in New Jersey.

Max Donley

Mr. Max Donley is an Executive Vice President of Global Human Resources, Information Technology and Strategy of the company since June 2014. Prior to joining Sucampo, Mr. Donley was the Executive Vice President of Human Resources and Corporate Affairs for MedImmune LLC, the global biologics arm of AstraZeneca, where he worked from 2000 to 2013. He served as the Director of Human Resources and Development at Bed, Bath, & Beyond from 1993 to 2000. This work helped build the human resources infrastructure that grew the company from 20 locations in 12 states to 254 locations in 39 states with revenues of $1.8B. Mr. Donley started his career at Fairfield Resources, where he worked from 1992 to 1993, and R.H. Macy & Co. Inc., where he worked from 1991 to 1992. Mr. Donley co-founded Axcelerant Health, a healthcare technology accelerator firm, where he remains a member of the Board of Directors. Mr. Donley earned a bachelor’s degree in general studies from the University of Michigan, and a master’s degree in business administration from George Mason University.

Matthias Alder

Mr. Matthias Alder, LL.M. has been appointed as the Executive Vice President of the Company, effective June 30, 2017. He currently serves as Executive Vice President, General Counsel, Corporate Secretary of the Company. Prior to joining Sucampo, he served from 2013 to October 2014 as Executive Vice President of Corporate Development and Legal Affairs and Corporate Secretary at Cytos Biotechnology AG, a biopharmaceutical company focused on the development of targeted immunotherapies. From 2006 to 2012 he held various roles of increasing responsibility, including Senior Vice President Administration, General Counsel and Secretary; Legal Affairs, Corporate Secretary and Compliance Officer; and Manager of Human Resources, Quality Assurance, Drug Safety and Intellectual Property at Micromet Inc., which was acquired by Amgen. Mr. Alder was also a partner in the Life Sciences Transactions Practice at Cooley LLP from 1997 to 2006, where he represented biotech companies in strategic transactions with pharmaceutical companies. Earlier in his career, Mr. Alder was in-house counsel at Ciba-Geigy and Novartis from 1994 to 1997. Mr. Alder earned law degrees from the University of Basel and the University of Miami and is qualified to practice law in Switzerland and the U.S.

Peter Kiener

Dr. Peter A. Kiener is a Chief Scientific Officer of the Company, since October 27, 2014. Prior to joining Sucampo, he served as CSO of Ambrx Inc., a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates, since 2013. From 2009 to 2013, Dr. Kiener was President and Co-founder of Zyngenia Inc., an early-stage biopharmaceutical company. He also held leadership roles of increasing responsibility from 2001 to 2009 at MedImmune LLC, the global biologics arm of AstraZeneca, including Executive Vice President and Global Head of Biologics Research and Development, Senior Vice President and Head of Global Research, and Vice President of Research. Dr. Kiener worked on biologics for Bristol-Myers Squibb from 1983 to 2001. He started his career at the University of North Texas/Texas College of Osteopathic Medicine, where he was an Assistant Professor from 1982 to 1983, and the University of Massachusetts at Amherst, where he was a Research Associate from 1978 to 1982. Dr. Kiener has served on the scientific advisory Boards of KAI Pharmaceuticals Inc., Genocea Biosciences Inc., NKT Therapeutics Inc. and VLST Corporation. Dr. Kiener has also served as a director of Receptor BioLogix Inc., Synovex Corporation and Virdante Pharmaceuticals Inc. He has published more than 120 papers in peer-reviewed journals and is an inventor on more than 40 patents and patent applications. He earned a bachelor’s degree in chemistry from the University of Lancaster and a doctorate of philosophy in biochemistry from the University of Oxford.

Alex Driggs

Mr. Alex Driggs serves as a General Counsel, Corporate Secretary of the Company. Mr. Driggs joined the Company in May 2015 as Associate General Counsel, was appointed its Deputy General Counsel in September 2015 and has most recently served as Acting General Counsel and Corporate Secretary since June 2017. Prior to joining Sucampo, from January 2013 through May 2015, Mr. Driggs was an independent legal consultant for biotechnology clients. From March until December 2012, Mr. Driggs served as Senior Counsel in Amgen Inc.’s Licensing & Alliance Management Group. Prior to joining Sucampo, from January 2013 through May 2015, Mr. Driggs was an independent legal consultant for biotechnology clients. From March until December 2012, Mr. Driggs served as Senior Counsel in Amgen Inc.’s Licensing & Alliance Management Group. From 2009 until 2012, Mr. Driggs was the Associate General Counsel for Micromet, Inc., a public biotechnology company that developed blinatumomab and other innovative antibody products. Mr. Driggs began his legal career at Cooley LLP as an associate in the Life Sciences and Technology Transactions groups. Mr. Driggs received his law degree from New York University School of Law and his undergraduate degree in Philosophy from Harvard University. He is a member of the Virginia State Bar.

Peter Lichtlen

Dr. Peter Lichtlen, M.D., Ph.D. is Chief Medical Officer of the company since July 2014. Chief Medical Officer of the company since July 2014. He also served as Sucampo’s Senior Medical Officer & Vice President of European Operations from 2011 to 2013. Prior to his appointment as CMO, Dr. Lichtlen was a consultant, providing support to the company in areas such as clinical development, reviews of protocols, the NICE endorsement for AMITIZA® in the U.K., European Medical Affairs activities, as well as medical support for the lubiprostone pediatric functional constipation program. Prior to joining the company, Dr. Lichtlen held various roles at ESBATech AG (acquired by Alcon/Novartis in 2009), of Schlieren, Switzerland, where he worked since 2000. He held several progressively more senior positions, culminating in being named Medical Director/Head, Clinical Research & Development, and a member of its senior management team, a position he held from 2004 to 2010. In that role, he was responsible for setting and managing clinical development strategy; serving as the scientific and medical lead for its clinical programs; overseeing interactions with regulatory agencies in Europe; and identifying new molecular targets and clinical indications, among other duties. Dr. Lichtlen also co-founded Numab AG, a Swiss biotechnology company that innovates antibody-based therapeutics, where he remains a member of the Board of Directors. He is a member of the Swiss Medical Association (FMH) and the Swiss Association of Pharmaceutical Professionals (SwAPP), the author of various peer-reviewed articles, and the holder of four patents. Dr. Lichtlen earned doctorate degrees in medicine and molecular biology at the University of Zurich.

John Johnson

Mr. John H. Johnson is a Lead Independent Director of the Company. He was Independent Director of Company. He served as the President and Chief Executive Officer of Dendreon Corporation, a biotechnology company focused on cancer, from 2012 to July 2014. Prior to that, Mr. Johnson served as the Chief Executive Officer of Savient Pharmaceuticals, Inc. from 2011 to 2012, as President of Eli Lilly & Company’s Oncology Unit following its 2008 acquisition of Imclone Systems, Inc., and he held various executive roles of increasing responsibility at Johnson & Johnson, where he worked from 1988 to 2007. Mr. Johnson is currently the chairman of the Board of Directors of Cortendo AB, a global biopharmaceutical company focused on orphan endocrine disorders. He also serves on the Board of Directors of Cempra Inc., a clinical-stage pharmaceutical company, Portola Pharmaceuticals, Inc., a biopharmaceutical company, and Histogenics Corporation, a regenerative medicine company. Previously, he served as a member of the Board of Directors of the Pharmaceutical Research and Manufacturers of America (PhRMA) and as a member of the Health Section Governing Board of Biotechnology Industry Organization (BIO). Mr. Johnson earned a bachelor’s degree from East Stroudsburg University of Pennsylvania.

Paul Edick

Mr. Paul R. Edick is director of the company. Mr. Edick became a Director of Sucampo in July 2016. He has served as president and chief executive officer of Xeris Pharmaceuticals since January 2017 and currently serves as Founding Partner at 3G Advisors, a consultancy to the pharmaceutical, healthcare and healthcare investor communities. From July 2010 to November 2014, Mr. Edick was Chief Executive Officer and board member of Durata Therapeutics, a publicly held biopharmaceutical company addressing the growing need for new antibiotics to treat infectious diseases that was acquired by Actavis in November 2014. Prior to Durata, he was Chief Executive Officer of Ganic Pharmaceuticals, Inc., a Warburg Pincus specialty pharmaceutical investment vehicle, and prior to that he was Chief Executive Officer at MedPoint Healthcare, Inc. Mr. Edick has also held a number of senior positions at GD Searle & Company, and at Pharmacia Corporation following its acquisition of the company, culminating in his appointment as Pharmacia’s Group Vice President and President for Asia and Latin America. He has served as a member of the Board of Directors of the public companies PDL BioPharma, Inc. since September 2015, of NewLink Genetics, Inc. since July 2011, and of Neos Therapeutics, Inc. since June 2015. Mr. Edick is also Chairman of the Board of Iterum Therapeutics, a private company. Mr. Edick earned a B.A. degree in Psychology from Hamilton College. Our board of directors believes the characteristics that qualify Mr. Edick for service on our board of directors include consistent leadership, extensive deal experience in the pharmaceutical industry and a deep understanding of the industry.

Daniel Getman

Dr. Daniel P. Getma, Ph.D., is a Director of the Company. He an Independent Chairman of the Board of Sucampo Pharmaceuticals, Inc., since March 3, 2014. Dr. Getman has been a Director for Sucampo since September 2011. He served as the President of Kansas City Area Life Sciences, Inc. (KCALSI) from 2009 until his retirement in July 2012. Dr. Getman joined KCALSI from Pfizer, Inc., where he had been Vice President of Global Research and Development and Director of Pfizer’s St. Louis laboratories from 2003 to 2008; Dr. Getman also served on Pfizer’s external research network committee, responsible for the Midwest region. Prior to joining Pfizer, Dr. Getman worked at Pharmacia Corporation, which merged with Pfizer in 2003, and G.D. Searle & Company and Monsanto Company. Dr. Getman’s own research experience spans medicinal chemistry in the areas of arthritis, cancer and infectious diseases, including a large program with G.D. Searle/Monsanto Pharmacia, before its merger with PharmaciaPfizer, on HIV Protease Inhibitors for AIDS that led to three separate licensing deals and two marketed products for AIDS patients – Lexiva® and Prezista®. He also serves as a member of the National Council for the Washington University School of Medicine, is a member of the Board of Managers for the Children’s Discovery Institute at Children’s Hospital/Washington University School of Medicine, and is an advisor to the Wisconsin Alumni Research Foundation catalyst accelerator program. He is currently Board Chair for the Missouri Biotechnology Association and a Board member of the Kansas Bioscience Organization. Dr. Getman earned a bachelor’s degree in chemistry from State University New York Buffalo and a doctorate in organic chemistry from the University of Minnesota.

Karen Smith

Dr. Karen L. Smith, M.D. Ph.D. M.B.A. LLM., has been appointed as Director of the Comapny, with effective from July 15, 2017. Dr. Smith brings to Sucampo over 25 years of senior leadership and executive experience with both major pharmaceutical companies and start-up biotechnology organizations. Her product development expertise spans various therapeutic areas and includes over 20 major drug and device approvals in North and Latin America, Asia, Europe and Australia. From 2011 to 2015, she was a Senior Vice President of Global Medical Affairs and Global Therapeutic Area Head for Allergan, a multi-specialty health care company. From 2007 to 2010, Dr. Smith served initially as AstraZeneca's Vice President of External Medical Relations, and later Vice President of Global Development. She held an array of management and medical roles at the Bristol-Myers Squibb Company in Australia, Canada and the United States. In 2001, she was also the Chief Executive Officer of Boron Molecular, a specialist fine chemicals manufacturing company. Dr. Smith previously served on the Women's Advisory Board for Ironman Corporation, Susan G. Komen and Girl Scouts; and is currently Advisor to the CEO of Forward Pharma. Dr. Smith holds a B.A.Sc. and a B.Sc. from the Curtin University, an M.D. from the University of Warwick (UK), a Ph.D. in oncology molecular genetics from the University of Western Australia, an M.B.A. from the University of New England (Australia) and a L.L.M. in medical law from the University of Salford (UK).

Timothy Walbert

Mr. Timothy P. Walbert is a Director of Sucampo Pharmaceuticals, Inc. Mr. Walbert joined Horizon in June 2008 as President and Chief Executive Officer and has served as Chairman of the Board of Directors since 2010. Prior to joining Horizon, Mr. Walbert served as President, Chief Executive Officer and Director of IDM Pharma, Inc., which was acquired by Takeda in June 2009. Prior to IDM, Mr. Walbert served as Executive Vice President, Commercial Operations at NeoPharm, Inc. From 2001 to 2005, Mr. Walbert served as Divisional Vice President and General Manager, Immunology, where he led the global development and launch of the multi-indication biologic HUMIRA and as Divisional Vice President, Global Cardiovascular Strategy at Abbott, now AbbVie. From 1998 to 2001, Mr. Walbert served as Director, CELEBREX North America and Arthritis Team Leader, Asia Pacific, Latin America and Canada at G.D. Searle & Company. From 1991 to 1998, Mr. Walbert also held sales and marketing roles with increasing responsibility at G.D. Searle, Merck & Co., Inc. and Wyeth. Mr. Walbert received his B.A. in business from Muhlenberg College. Mr. Walbert serves as Chairman of the Board of Egalet Corporation and sits on the Board of Directors of XOMA Corporation, the Pharmaceutical Research and Manufacturers of America (PhRMA), the Biotechnology Industry Organization (BIO), the Illinois Biotechnology Industry Organization (iBIO), ChicagoNEXT, a World Business Chicago (WBC) led council of technology leaders and the Greater Chicago Arthritis Foundation. Mr. Walbert is also a member of the Illinois Innovation Council.

Barbara Munder

Ms. Barbara A. Munder is an Independent Director of Sucampo Pharmaceuticals, Inc., since February 27, 2013. Since 2005, Ms. Munder serves as Senior Advisor at Institutional Investor LLC, an international business-to-business publisher. From 2001 to 2005, she was Executive Director of the Institutional Investor Institute and The Hedge Fund Institutional Forum, Institutional Investor LLC. From 2001 to 2002, she was a principal of Munder & Associates, a marketing- and web-strategy consulting firm. Also in 2001, Ms. Munder served as Chief Operating Officer at Womenfuture LLC, a distance learning company, where she oversaw e-business strategy. From 1994 to 2000, Ms. Munder held various positions with The McGraw-Hill Companies, Inc., including Senior Vice President, New Initiatives, with oversight for corporate-wide electronic commerce, and Senior Vice President, Corporate Affairs, with responsibility for branding, marketing, communications, and Washington affairs. Ms. Munder also served as a director of PetSmart Inc. and serves as director of Munder Realty Corporation, a private real estate firm. Additionally, she has been on the advisory board for DOAR, a private litigation information services and consulting firm; Izzo Systems, a manufacturer of ergonomically designed golf bags and straps; and Lighthouse International, a non-profit for the visually impaired. Ms. Munder holds a B.A. in political science from Elmira College and a M.B.A. in Finance from New York University, Stern School of Business Administration.

Maureen O'Connell

Ms. Maureen E. O'Connell is Independent Director of Sucampo Pharmaceuticals, Inc., since February 27, 2013. Since 2007, Ms. O’Connell has been the Executive Vice President, Chief Administrative Officer and Chief Financial Officer at Scholastic Inc. Ms. O’Connell has overall responsibility for finance, human resources, information technology, customer service, facilities, supply chain, and manufacturing. From 2005 to 2006, she served as Executive Vice President and Chief Financial Officer at Affinion Group, Inc., a leading affinity direct marketer of membership, insurance and loyalty programs. From 2002 to 2004, she held a series of progressively more responsible positions, including President and Chief Operating Officer and Executive Vice President, Chief Financial and Administrative Officer at Gartner, Inc., a leading technology research and advisory firm. From 2000 to 2002, she worked at Barnes & Noble, as their Executive Vice President and Chief Financial Officer. From 1998 to 2000, she was the Chief Financial Officer and Vice President at Publishers Clearing House. She worked as the Senior Vice President of Finance and Marketing Analysis at BMG Direct from 1997 to 1998. From 1990 to 1997, she held a series of positions at Primedia, Inc., most recently as Chief Financial Officer and Senior Vice President. Ms. O’Connell is a former member of the board of directors of Beazer Homes from 2002 to 2007, where she served as audit chair for most of her tenure. Ms. O’Connell holds a B.S. in Accounting and Economics from New York University, Stern School of Business Administration and is a Certified Public Accountant in the State of New York. Our board of directors believes the characteristics that qualify Ms. O’Connell for service on our board of directors include her senior leadership experience in finance and operations, including in particular her previous experience as a chief financial officer for seven companies.

Robert Spiegel

Dr. Robert J. Spiegel, M.D., FACP is an Independent Director of Company. Dr. Spiegel was Chief Medical Officer of Schering-Plough and was involved in the successful filing of over 30 New Drug Applications. He also served on the executive committees overseeing research projects and drug licensing activities. Dr. Spiegel joined Schering-Plough in 1983 as Director, Clinical Research, progressing through clinical operations as Vice President of Clinical Research, Senior Vice President of Worldwide Clinical Research and then becoming Chief Medical Officer in 1998. He received his undergraduate degree, cum laude, from Yale University and his medical degree from the University of Pennsylvania. He is currently an Associate Professor at Weill Cornell Medical Center and serves on the board of directors and scientific advisory committees of a number of companies. Dr. Spiegel also currently serves as Chief Medical Officer at PTC Therapeutics.

Silvia Taylor

Ms. Silvia Taylor is a Senior Vice President - Investor Relations and Corporate Communications of Sucampo Pharmaceuticals, Inc. She brings 20 years of marketing and communications experience to Sucampo, including five years in public and media relations and 13 years in biopharmaceutical brand marketing at MedImmune and Pfizer Inc. She has experience in marketing, strategy, new product launches, social media, direct-to-consumer advertising, communications, and public health, and has held leadership roles for Viagra, Exubera, motavizumab, Synagis and FluMist as well as other pre-launch products. Ms. Taylor joins Sucampo from MedImmune where she held positions of increasing responsibility, among them Senior Director of Marketing, RSV Franchise and Senior Director of Marketing, Global Influenza Franchise. Prior to MedImmune, Ms. Taylor worked at Pfizer from 1999 to 2007, where she worked on Viagra and Exubera and in the company's consumer marketing department on patient-directed communications. Ms. Taylor's work has won numerous marketing and pharmaceutical industry awards. She graduated from the University of Virginia with a B.A. in Foreign Affairs and from Columbia Business School where she earned an MBA in Marketing and Management.

Basic Compensation